Anika Therapeutics generates an annual revenue hovering around $112 million to $121 million based on recent fiscal reporting periods. As a specialized joint preservation and orthopedic commercial enterprise, its top-line financial results reflect steady performance across its global commercial channels, viscosupplement product lines, and regenerative medicine portfolios, fluctuating moderately in accordance with international distribution demands and strategic corporate developments.